ABSTRACT
Gilles de la Tourette syndrome (TS) is a neurodevelopmental disorder characterised by multiple motor tics and at least one vocal tic that have been present for over a year and onset before 18 years; according to the Diagnostic and Statistical Manual of the American Psychiatric Association and the International Classification of Disorders. The Gilles de la Tourette Syndrome-Quality of Life Scale assesses health-related quality of life in young patients with Tourette syndrome, across four subscales (psychological, physical, obsessional and cognitive). It has demonstrated satisfactory scaling assumptions and acceptability, as well as internal consistency, reliability and test-retest reliability and sound validity. The assessment of comorbid conditions requires tools specific to the respective conditions and is beyond the scope of this chapter. With regards to the use of pharmacological agents in the management of TS, Seignot was the first to describe the beneficial effects of haloperidol.
